A comparative pharmacodynamic and pharmacokinetic study of Vildagliptin SR 100 mg tablet in normal healthy adult male subjects

  • Sona Warrier Scientific Services, USV Private Limited, Mumbai, Maharashtra, India
  • Harish R Joshi Endocrine and Diabetes Care Center, Hubli, Karnataka, India
  • Nidhi Joshi DY Patil Medical College, Kolhapur, Maharashtra, India

Abstract

Background: Vildagliptin, a potent dipeptidyl peptidase IV inhibitor (DPP-4i), is usually administered twice daily to provide ≥90% inhibition of DPP-4 over 24 hours. Considering most type 2 diabetes (T2D) patients are on multiple medications, reducing dosing and pill burden can increase patient convenience. A 100 mg Vildagliptin sustained release (SR) formulation that would inhibit DPP-4 ≥ 80% over 24 hours with a lower dosing frequency was developed. The study was thus conducted to evaluate the pharmacodynamics, pharmacokinetics, and safety profile of once-daily Vildagliptin SR compared to twice-daily Vildagliptin immediate-release (IR) formulation.


Results: Twenty-four healthy adult male subjects were enrolled, and 22 completed the clinical phase of the study. The DPP-4 inhibition over time was comparable between the formulations. At 24 hrs single dose of once-daily Vildagliptin SR 100 mg tablet inhibited DPP4 by 89.58%, whereas twice-daily Vildagliptin IR 50 mg by 91.052%. The pharmacokinetic parameters like peak plasma concentration (Cmax), area under the plasma concentration-time curve from 0 hours to the last measurable concentration (AUC0-t) and AUC-time curve up to infinity (AUC0-inf) were not significantly different in both groups. Besides this, both groups reported no serious adverse effects during the study period.


Conclusion: The above result shows that once-daily Vildagliptin SR 100 mg is bioequivalent to twice-daily Vildagliptin IR 50 mg. Moreover, the ability of Vildagliptin SR 100 mg to provide above 80% DPP-4 inhibition coverage over 24 hrs may help to achieve a clinically meaningful glucose-lowering effect and reduce the pill burden in diabetes patients.


Keywords: Vildagliptin, dipeptidyl peptidase IV inhibitor (DPP-4i), type 2 diabetes (T2D) patients, pharmacokinetic parameters

Keywords: Vildagliptin, dipeptidyl peptidase IV inhibitor (DPP-4i), type 2 diabetes (T2D) patients, pharmacokinetic parameters

Downloads

Download data is not yet available.

Author Biographies

Sona Warrier, Scientific Services, USV Private Limited, Mumbai, Maharashtra, India

Scientific Services, USV Private Limited, Mumbai, Maharashtra, India

Harish R Joshi, Endocrine and Diabetes Care Center, Hubli, Karnataka, India

Endocrine and Diabetes Care Center, Hubli, Karnataka, India

Nidhi Joshi, DY Patil Medical College, Kolhapur, Maharashtra, India

DY Patil Medical College, Kolhapur, Maharashtra, India

References

1. Gallwitz B. Clinical Use of DPP-4 Inhibitors. Front Endocrinol (Lausanne). 2019 Jun 19; 10:389. https://doi.org/10.3389/fendo.2019.00389
2. Pote A, Ravisankar S, Sangle G, Agarwal S, Yarramshetti V, Kale S, Baig ML, Deshmukh S, Shah R, Debnath K, Chitalkar K. Comparative Clinical Pharmacokinetics and Pharmacodynamics of Investigational Once-Daily Sustained-Release (SR) Vildagliptin 100 mg Tablet Formulation with Conventional 50 mg Twice-Daily Regimen in Healthy Indian Males. IJCSRR, 2021; 4(5):445-456 https://doi.org/10.47191/ijcsrr/V4-i5-19
3. García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther. 2013 Dec; 4(2):175-94. https://doi.org/10.1007/s13300-013-0034-y
4. Narwate BM. Sustained release dosage form: a concise review. International journal of pharmaceutics and drug analysis. 2017 May 2:153-60.
5. Nagendrakumar D, Keshavshetti GG, Shardor AG. An overview: Matrix tablets as sustained release. Recent Research in Science and Technology. 2014 Jan 14; 5(4). https://doi.org/10.5530/rjps.2015.3.4
6. Pote, A., Ravisankar, S., Sangle, G., Agarwal, S., Patil, M., Deshmukh, N., Kale, S., Baig, M., Yarramshetti, V., Debnath, K., Shah, R., Ingole, S., & Jain, R. (2021). Clinical pharmacokinetics and pharmacodynamics of vildagliptin 50 mg sustained release tablet formulation in healthy Indian males after single and multiple-dose. International Journal of Research in Medical Sciences, 9(2), 510-517. https://doi.org/10.18203/2320-6012.ijrms20210433
7. Hauber AB, Han S, Yang JC, Gantz I, Tunceli K, Gonzalez JM, Brodovicz K, Alexander CM, Davies M, Iglay K, Zhang Q, Radican L. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes. Patient Prefer Adherence. 2013 Sep 18; 7:937-49. https://doi.org/10.2147/PPA.S43465
8. Jabbour S, Ziring B. Advantages of extended-release metformin in patients with type 2 diabetes mellitus. Postgrad Med. 2011 Jan; 123(1):15-23. https://doi.org/10.3810/pgm.2011.01.2241
9. Xie W, Song X, Liu Z. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascul Pharmacol. 2018 Oct; 109:17-26. https://doi.org/10.1016/j.vph.2018.05.010
Statistics
114 Views | 3 Downloads
How to Cite
1.
Warrier S, Joshi HR, Joshi N. A comparative pharmacodynamic and pharmacokinetic study of Vildagliptin SR 100 mg tablet in normal healthy adult male subjects. JDDT [Internet]. 15Nov.2022 [cited 9Dec.2022];12(6):22-6. Available from: https://jddtonline.info/index.php/jddt/article/view/5760